A class action lawsuit has been filed against Erasca, Inc. and its executives for allegedly making false and misleading statements about their lead oncology drug candidate, ERAS-0015, during January 2025 to April 2026. The lawsuit claims Erasca overstated the drug's potential and failed to disclose patent and trade secret issues, causing investor losses when the truth emerged. Investors who bought Erasca stock during this period may be eligible for compensation. Those interested in joining the lawsuit or serving as lead plaintiff must act by August 10, 2026.
OpenAI has acquired cloud-based developer Ona to enhance its Codex AI platform with secure, customer-controlled cloud infrastructure. This acquisition enables Codex to perform long-running AI tasks across devices and sessions, even when offline, sign...
L.B. Foster Company announced that its executives Bill Thalman and Sean Reilly will present virtually at the Sidoti Small Cap Virtual Conference on June 18, 2026. The presentation will start at 10:45 AM EDT, with materials available on the company's ...
Stifel Nicolaus raised Kimco Realty's price target to $28, signaling a 9.18% potential gain as the company successfully upsized its exchangeable senior notes offering from $500 million to $525 million due to strong investor demand. These notes, with ...
Dogecoin (DOGE) faces pressure after breaking key support, needing to reclaim $0.10 to regain bullish momentum. Shiba Inu (SHIB) remains under seller control but may consolidate if support holds. Toncoin (TON) shows resilience, stabilizing near suppo...
Arcadium Lithium plc's stock recently dipped about 4.92% over the past 10 days after gaining nearly 7% in the last month, presenting a possible buying opportunity. Analysts forecast a significant 40.14% growth potential with an average target price o...
